Living Devices
Xeltis restorative pulmonary heart valve
Fully synthetic restorative pulmonary heart valve for Right Ventricular Outflow Tract reconstruction, overtime turning into a living heart valve made of patient’s own tissue.
Status: Three ongoing clinical trials in pediatric patients.
Results: Clinical results published in Frontiers in Cardiovascular Medicine.
Xeltis aortic heart valve
Xeltis restorative electrospun aortic heart valve for trans-apical and potentially transcatheter implantation, overtime turning into a living heart valve made of patient’s own tissue.
Status: Proof-of-concept from long-term preclinical trials completed.
Results: Preliminary results published in Eurointervention.
The XABG device is a restorative, synthetic, electrospun blood vessels for CABG surgery, overtime turning into a living vessel made of patient’s own tissue.
Status: Proof-of-concept and preclinical trials complete; First-in-human trial initiation.
Results: First-ever synthetic CABG device to succeed in preclinical trials, with graft consistently open for 6-12 months; proven tissue regeneration in the internal part of the vessel, protecting from thrombosis and other negative side effects; long term durability with successful endothelialization at one year.
The aXess graft is a restorative, synthetic, electrospun blood vessel for arteriovenous hemodialyisis access, overtime turning into a living vessel made of patient’s own tissue.
Status: Proof-of-concept and preclinical trials completed; First-in-human trial initiation.
Results: Successful formation of functional, living 20 cm long graft in one-year preclinical study. Improved healing compared to commercially available synthetic grafts ePTFE.
Key Technology Benefits
01 Technology safety
Xeltis’ restorative technology has been used for over 60 patient/years across cardiovascular applications to date
02 Reduced intervention
Xeltis’ cardiovascular devices may help reduce the need for repeated replacement procedures, invasive vessel harvesting or long-term medication
03 Growth potential
New, living devices developed with patient’s own tissue have the potential to grow as patients grow-up. Long-term clinical data will further provide supporting evidence
04 Low infection
Xeltis’ restorative devices may help reduce infection rates from recurrent operations, vein harvesting surgery or devices permanently implanted in the body
05 Availability
Xeltis’ implants are off-the-shelf devices made of polymers and ready to use. The devices do not depend on animal tissue or human tissue supplies
06 Cost-effectiveness
Xeltis’ restorative devices may help reduce the overall cost of blood vessel and heart valve replacement
Product Pipeline
Pediatric conduit
Pulmonary Heart Valve
Blood vessels – CABG
Blood vessels – Hemodialysis
Aortic Heart Valve
Nobel Prize-Awarded Science
Jean-Marie Lehn, Nobel Laureate.
Awarded 1987 Nobel Prize in Chemistry for pioneering supramolecular chemistry, the science at the basis of Xeltis’ technology.
“Supramolecular chemistry enables Xeltis technology by providing unique biochemical and biomechanical properties, delivering solutions to issues faced by traditional materials over the course of decades.”
Professor Lehn is a Scientific Advisor to Xeltis.
